Teva Pharmaceutical Industries Ltd. ADR 1.42% $19.56B ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 38,541.57 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...

SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...